608
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of the Antinociceptive and Anti-inflammatory Activities of Satureja thymbra. L. Essential Oil

, , , &
Pages 585-591 | Accepted 20 Jun 2006, Published online: 07 Oct 2008

Figures & data

Table 1. Chemical composition of the essential oil of S. thymbra..

Figure 1 Antinociceptive effect of S. thymbra. extract (mg kg−1, i.p.) determined as the effect on early phase (striped columns) and late phase (dotted columns) formalin-induced hind-paw licking behavior in mice. Results indicate hind-paw licking time in seconds (s) and are mean±SEM, n = 10 for each group. Essential oil (12.5, 25, 50, 100 mg kg−1), vehicle (2% Tween 20) (control), morphine, morphine + naloxone, or essential oil + naloxone were administered before the formalin injection. EO, essential oil of S. thymbra., M, 10 mg kg−1 morphine; M + N, 10 mg kg−1 morphine + 2 mg kg−1 naloxone; EO + N, 100 mg kg−1 essential oil of S. thymbra. + 2 mg kg−1 naloxone administration. #p < 0.01 according to control animals. p < 0.05 according to morphine group.

Figure 1 Antinociceptive effect of S. thymbra. extract (mg kg−1, i.p.) determined as the effect on early phase (striped columns) and late phase (dotted columns) formalin-induced hind-paw licking behavior in mice. Results indicate hind-paw licking time in seconds (s) and are mean±SEM, n = 10 for each group. Essential oil (12.5, 25, 50, 100 mg kg−1), vehicle (2% Tween 20) (control), morphine, morphine + naloxone, or essential oil + naloxone were administered before the formalin injection. EO, essential oil of S. thymbra., M, 10 mg kg−1 morphine; M + N, 10 mg kg−1 morphine + 2 mg kg−1 naloxone; EO + N, 100 mg kg−1 essential oil of S. thymbra. + 2 mg kg−1 naloxone administration. #p < 0.01 according to control animals. ⋆p < 0.05 according to morphine group.

Figure 2 Latency to withdraw the tail from noxious thermal stimulation in rats after treatment with 2% Tween 20 (control) and 50, 100, and 200 mg kg−1 i.p. S. thymbra. essential oil injection. Data are expressed as mean and vertical lines show SEM (n = 10 for each group). EO, essential oil of S. thymbra.; M, 10 mg kg−1 morphine; M + N, 10 mg kg−1 morphine + 2 mg kg−1 naloxone; EO + N, 100 mg kg−1 essential oil of S. thymbra. + 2 mg kg−1 naloxone administration. *p < 0.05, #p < 0.01 according to control animals. p < 0.05, ·⋄p < 0.01 according to morphine group. θp < 0.01 according to 100 mg kg−1 EO.

Figure 2 Latency to withdraw the tail from noxious thermal stimulation in rats after treatment with 2% Tween 20 (control) and 50, 100, and 200 mg kg−1 i.p. S. thymbra. essential oil injection. Data are expressed as mean and vertical lines show SEM (n = 10 for each group). EO, essential oil of S. thymbra.; M, 10 mg kg−1 morphine; M + N, 10 mg kg−1 morphine + 2 mg kg−1 naloxone; EO + N, 100 mg kg−1 essential oil of S. thymbra. + 2 mg kg−1 naloxone administration. *p < 0.05, #p < 0.01 according to control animals. ⋆p < 0.05, ·⋄p < 0.01 according to morphine group. θp < 0.01 according to 100 mg kg−1 EO.

Table 2. Effect of S. thymbra. essential oil on the latency time of rats submitted to the hot-plate test.

Figure 3 Percent increase in carrageenan-induced paw edema in control rats treated with vehicle (2% Tween 20), in rats treated with 50, 100, and 200 mg kg−1 S. thymbra., and 10 mg kg−1indomethacin. Percent increment in paw swelling was calculated by using the values before carrageenan injection. Data are expressed as mean and vertical lines show SEM (n = 10 for each group). *p < 0.05, #p < 0.01 vs. control. EO, essential oil of S. thymbra..

Figure 3 Percent increase in carrageenan-induced paw edema in control rats treated with vehicle (2% Tween 20), in rats treated with 50, 100, and 200 mg kg−1 S. thymbra., and 10 mg kg−1indomethacin. Percent increment in paw swelling was calculated by using the values before carrageenan injection. Data are expressed as mean and vertical lines show SEM (n = 10 for each group). *p < 0.05, #p < 0.01 vs. control. EO, essential oil of S. thymbra..

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.